News

Under the terms of the agreement, Bristol-Myers will pay $150m in cash up front for the right to buy Promedior. Bristol-Myers can exercise its right after Promedior completes

The company will complete screening at participating sites in the next two weeks. Enrollment is anticipated to be completed by the end of the third quarter. Twirla is

Bacterial vaginosis (BV) is the most common vaginal infection in women of childbearing age which is caused due to an imbalance of naturally occurring vaginal bacterial flora. Laccure

Perrigo’s expansive distribution and customer network in the US will be used to boost ScarAway’s growth. ScarAway is expected to have net sales of around $10m in full,

French pharmaceutical firm Sanofi will work with Google’s life sciences team to collect, analyze and understand information impacting diabetes. According to the International Diabetes Federation, diabetes is anticipated

The agreement formalizes a relationship between QB3@953 and GSK’s Discovery Partnerships with Academia (DPAc) team and creates a new channel for DPAc to identify early-stage opportunities. The agreement

The Israeli patent application No. 207420 is entitled "Methods and Compositions for Treating Inflammatory Bowel Disease". Once granted, the patent is expected to be valid through at least

Cobimetinib is a selective inhibitor of MEK that was discovered by Exelixis and is the subject of a worldwide collaboration agreement between Exelixis and Genentech, a member of

The deal is part of the Belgian firm’s intention to expand the global footprint of C-Cure to treat ischemic heart failure. As part of the deal, Celyad will